Our Companies
Innovation meets execution. We invest in differentiated technology and support the growth of our portfolio companies through hands-on partnership
Mirus Bio
The Transfection Experts
Year Invested: 2021
Stage at Time of Investment: Established Commercial - RUO
Company Overview:
Mirus Bio is a leading provider of transfection products for the biopharmaceutical and research industries, offering best-in-class reagents for cell and gene therapy, recombinant protein expression, and stem cell applications. An original pioneer in nucleic acid delivery, the company has been enabling scientific research and innovation for more than two decades.
Astrea Bioseparations
Purity by Design
Year Invested: 2019
Stage at Time of Investment: Established Commercial - GMP
Company Overview:
Astrea Bioseparations is a leading provider of chromatography solutions for the life sciences industry. With products used in the manufacture of over 20 approved therapeutic and medical products, Astrea Bio is trusted by scientists around the world to deliver precise, reliable purification.
Nanopareil
Game-Changing NanoFiber Chromatography
Year Invested: 2020 (Combined with Astrea in 2021)
Stage at Time of Investment: Pre-Commercial
Company Overview:
Nanopareil was spun out of the South Dakota School of Mines in 2011 to develop a novel, electro-spun cellulose nanofiber material for biological separation applications. Following Gamma’s investment in 2020, the company was combined with Astrea Bioseparations to accelerate launch of its initial product line, AstreaAdept for the purification of large molecules such as AAV and LV in cell and gene therapy applications
Univercells Technology
The Next Evolution of Biomanufacturing
Year Invested: 2020
Stage at Time of Investment: Early Commercial - GMP
Company Overview:
Univercells Technologies provides innovative biomanufacturing products based on a unique, ‘structured, fixed-bed’ perfusion bioreactor design for more cost-effective viral production from R&D to commercial scales. In addition to this novel design, the platform utilizes process intensification and chaining to deliver increased performance with minimized footprint and costs.
BioMagnetic Solutions
Cell Selection, Simplified
Year Invested: 2021
Stage at Time of Investment: Pre-Commercial
Company Overview:
Magnetic particles (ferrofluids) combined with a variety of GMP-grade antibodies suitable for clinical applications. The platform offers clinicians, biomedical scientists, and researchers a vastly simpler and higher performance alternative to existing immunomagnetic cell separation systems.
Nirrin Technologies
Advanced Process Analytics
Year Invested: 2021
Stage at Time of Investment: Pre-Commercial
Company Overview:
Nirrin is developing sophisticated bioprocess analytical systems (PAT) utilizing high-precision tunable laser spectroscopyTM (HPTLS) and advanced software technology. The company is a pioneer in applying near infrared (NIR) spectroscopy across the bioprocessing workflow.